Insider · CIK 0001145910
Benjamin R Yerxa
Files at IRD (Ocuphire Pharma, Inc.). First filing Nov 25, 2024, latest Jul 27, 2026.
In brief
Benjamin R Yerxa files SEC Form 4 as president and director at IRD (Ocuphire Pharma, Inc.). Since Nov 25, 2024, Benjamin R Yerxa has reported 1 open-market buy worth $9,834 and 2 open-market sells worth $61k, the latest filed on Jul 27, 2026.
A track record needs three past buys with six months of prices behind them; Benjamin R Yerxa has 1, so none is measured yet.
The newest scored trade: sold $22k of IRD on Jul 23, 2026, filed Jul 27, 2026, scored 35 (weak). In the last 12 months: 0 buys worth $0 and 2 sells worth $61k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
IRD: Ocuphire Pharma, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 35Weak | Ocuphire Pharma, Inc. | $22k 7,429 shares | -1% | +175% from low-49% from high | |
| 41Moderate | Ocuphire Pharma, Inc. | $39k 7,470 shares | -1% | +586% from low-9% from high | |
| 28Weak | Ocuphire Pharma, Inc. | $9,834 10,000 shares | +3% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 23, 2026 | IRD Opus Genetics, Inc. | 7,429 0.01% of outstanding | $22k | Jul 23, 2026 | $39k |
| Apr 23, 2026 | IRD Opus Genetics, Inc. | 7,470 0.01% of outstanding | $39k | Apr 23, 2026 | none |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 23, 2026 | IRD Ocuphire Pharma, Inc. | SOpen-market sale Common Stock | -7,429 | $2.97 | $22k | 704,106 | Jul 27, 2026 |
| Apr 23, 2026 | IRD Ocuphire Pharma, Inc. | SOpen-market sale Common Stock | -7,470 | $5.24 | $39k | 711,535 | Apr 27, 2026 |
| Jan 22, 2026 | IRD Ocuphire Pharma, Inc. | AGrant or award Common Stock | +400,000 | $0.00 | $0 | 719,005 | Jan 26, 2026 |
| Oct 22, 2025 | IRD Ocuphire Pharma, Inc. | FTax withholding Common Stock | -23,795 | $1.95 | $46k | 319,005 | Oct 24, 2025 |
| Nov 21, 2024 | IRD Ocuphire Pharma, Inc. | POpen-market purchase Common Stock | +10,000 | $0.98 | $9,834 | 342,800 | Nov 25, 2024 |
| Nov 7, 2024 | IRD Ocuphire Pharma, Inc. | AGrant or award Common Stock | +332,800 | $0.00 | $0 | 332,800 | Nov 12, 2024 |
Questions about Benjamin R Yerxa
Answered from the filings on this page, as of the latest one.
Is Benjamin R Yerxa buying or selling?
In the last 12 months Benjamin R Yerxa reported 0 open-market buys worth $0 and 2 open-market sells worth $61k on SEC Form 4; the latest was sold $22k of IRD on Jul 23, 2026. Grants, option exercises and tax withholding are not counted.
How did Benjamin R Yerxa's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Benjamin R Yerxa has 1.
Where does Benjamin R Yerxa file Form 4?
Benjamin R Yerxa has filed Form 4 at IRD (Ocuphire Pharma, Inc.) as President. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.